SKP.L Regulatory News (SKP)

28 Jul 2006 12:00

Skyepharma PLC28 July 2006 For Immediate Release 28 July 2006 SkyePharma PLC LONDON, UK, 28 July 2006 -- In compliance with NASDAQ Marketplace Rule 4350 (b)1(B) SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces that the independent auditreport included in the Company's UK Annual Report and Annual Report on Form 20-Ffor the year ended 31 December 2005 contained an explanatory paragraph relatingto the Company's ability to continue as a going concern. Management plans withregard to these matters are described in Note 1 to the financial statements. Thedisclosure in this press release is required under the aforementioned NASDAQrule and does not represent any change to the Company's Annual Reports for theyear ended 31 December 2005. For further information please contact:SkyePharma PLC +44 207 491 1777Peter Laing, Director of Corporate Communications +44 207 491 5124Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now twelve approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock Exchange